Tempest Therapeutics Announces Senlang Collaboration to Advance TPST-4003 In Vivo CAR-T Pipeline and Appoints Two New Directors
Tempest Therapeutics announced a collaboration with Senlang Biotechnology to advance its TPST-4003 in vivo CAR-T product candidates, targeting first patient dosing in late 2026 and initial clinical data in early 2027. The company also appointed Drake Richey and Dr. John Yee to its Board …